Kintara Therapeutics Inc
KTRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.78M
Close$
Share Statistics
| Market cap | $13.78 Million |
|---|---|
| Enterprise Value | $7.94 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.63 |
| Beta | 0.81 |
| Outstanding Shares | 63,963,513 |
Return
| Return on Equity | -144.00% |
|---|---|
| Return on Assets | -112.42% |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.04 |
|---|---|
| PEG | 127.96 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 14, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kintara Therapeutics Inc
22 employees
CEO: Saiid Zarrabian TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mecha...